Montreal General Hospital’s PET Services relocated temporarily at the Glen site. Learn more .

Watch, Learn, Vote! Five years of research in 3 minutes: Dr. Jean-Jacques Lebrun’s team discovers promising treatment for triple negative breast cancer

Dr. Jean-Jacques Lebrun and his team at the Research Institute of the McGill University Health Centre (RI-MUHC) have discovered a promising treatment for triple negative breast cancer (TNBC), a particularly aggressive and deadly cancer. Their discovery has made Quebec Science’s top ten discoveries of 2021 and could be voted as Discovery of the Year. The public gets to decide by voting on the contest’s website.

Curious to learn more about the discovery that brings hope of finally offering an effective treatment to women suffering from TNBC? Watch this animation that will take you through the steps of this extraordinary research. More than five years of effort summarized in just over three minutes!

Hurry! Voting closes on February 10, 2022 at 11:59 p.m. Vote here for Dr. Lebrun's discovery (discovery #5).

About the study

The study “In vivo Genome-Wide CRISPR Screen Reveals Breast Cancer Vulnerabilities and synergistic mTOR/Hippo Targeted Combination Therapy”, published in Nature Communications in June 2021, was conducted by Meiou Dai, Gang Yan, Ni Wang, Girija Daliah, Ashlin M Edick, Sophie Poulet, Julien Boudreault, Suhad Ali, Sergio A Burgos and Jean-Jacques Lebrun. This research was supported by funds from the Canadian Institutes for Health Research (CIHR).

Read the press release about the study